Hexima Ltd released its earnings results on Aug 29, 2024. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.

Q: Is Hexima Ltd overvalued?

According to Wall Street analysts Hexima Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: How many shares outstanding does Hexima Ltd have?

Hexima Ltd has 167,039,630 shares outstanding.

Q: What happened to Hexima Ltd’s price movement after its last earnings report?

Hexima Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

0 Followers

HXL Stock Chart & Stats

Advanced Chart >

Day’s Range― - ―

52-Week Range<AU$0.01 - AU$0.02

Previous CloseN/A

Volume15.80K

Average Volume (3M)0.00

Market Cap

AU$2.17M

Enterprise Value-AU$388.78K

Total Cash (Recent Filing)$3.42M

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-1.38

Next Earnings

Feb 20, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding167,039,630

10 Day Avg. Volume0

30 Day Avg. Volume0

Standard Deviation0.31

R-Squared0.03

Alpha0.00645

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.18

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Hexima Ltd News

PremiumCompany Announcements

Hexima Ltd Announces Cessation of Securities Options

6d ago

HXL

PremiumCompany Announcements

Hexima Ltd Cancels Securities Issuance Plan

2M ago

HXL

PremiumCompany Announcements

Hexima Ltd Cancels Share Issue Plans

2M ago

HXL

PremiumCompany Announcements

Hexima Ltd Cancels Acquisition, Explores New Opportunities

2M ago

HXL

PremiumCompany Announcements

Hexima Ltd Sees Strong Shareholder Support at AGM

2M ago

HXL

PremiumCompany Announcements

Hexima Limited Pursues Strategic Acquisition Amidst Financial Update

3M ago

HXL

PremiumCompany Announcements

Hexima Limited to Hold Virtual AGM in 2024

3M ago

HXL

PremiumCompany Announcements

Hexima Limited Announces 2024 Annual General Meeting

3M ago

HXL

See More AU:HXL News >

Financials

Annual

Income Statement >

HXL FAQ

What was Hexima Ltd’s price range in the past 12 months?

Hexima Ltd lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.

What is Hexima Ltd’s market cap?

Hexima Ltd’s market cap is AU$2.17M.

When is Hexima Ltd’s upcoming earnings report date?

Hexima Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 32 days.

How were Hexima Ltd’s earnings last quarter?

Hexima Ltd released its earnings results on Aug 29, 2024. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.

Is Hexima Ltd overvalued?

According to Wall Street analysts Hexima Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hexima Ltd pay dividends?

Hexima Ltd does not currently pay dividends.

What is Hexima Ltd’s EPS estimate?

Hexima Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hexima Ltd have?

Hexima Ltd has 167,039,630 shares outstanding.

What happened to Hexima Ltd’s price movement after its last earnings report?

Hexima Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Hexima Ltd?

Currently, no hedge funds are holding shares in AU:HXL

---

Hexima Ltd Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-38.89%

Trailing 12-Months

Asset Growth

-23.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Hexima Ltd

Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics. It is developing a product for the treatment of fungal nail infections.

---